DE3517998C1 - - Google Patents
Info
- Publication number
- DE3517998C1 DE3517998C1 DE3517998C1 DE 3517998 C1 DE3517998 C1 DE 3517998C1 DE 3517998 C1 DE3517998 C1 DE 3517998C1
- Authority
- DE
- Germany
- Prior art keywords
- lithium
- dimethandrostenolone
- methandrostenolone
- methylated
- depression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 8
- 229910052744 lithium Inorganic materials 0.000 claims description 7
- XWALNWXLMVGSFR-HLXURNFRSA-N Methandrostenolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 XWALNWXLMVGSFR-HLXURNFRSA-N 0.000 claims description 5
- 230000001430 anti-depressive Effects 0.000 claims description 5
- 239000000935 antidepressant agent Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 3
- INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Chemical compound [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 claims description 3
- 229960003377 Metandienone Drugs 0.000 claims description 2
- 229940042009 Methandrostenolone Drugs 0.000 claims description 2
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 claims description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N Chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 claims 1
- 229940050176 Methyl Chloride Drugs 0.000 claims 1
- 229940087748 lithium sulfate Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
- 229960003638 dopamine Drugs 0.000 description 5
- 229940005513 ANTIDEPRESSANTS Drugs 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229910003002 lithium salt Inorganic materials 0.000 description 2
- 159000000002 lithium salts Chemical class 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- WDIHJSXYQDMJHN-UHFFFAOYSA-L Barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 210000001218 Blood-Brain Barrier Anatomy 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 206010012378 Depression Diseases 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 229960003604 Testosterone Drugs 0.000 description 1
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testosterone Natural products O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000003595 spectral Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003515 testosterones Chemical class 0.000 description 1
Description
Beschreibung Titel (technische Bezeichnung): Antidepressivum bestehend aus einer Verbindung aus methyliertem Methandrostenolon (= Dimethandrostenolon) und dem elementaren Lithium. Description Title (technical name): Antidepressant consisting from a compound of methylated methandrostenolone (= dimethandrostenolone) and the elemental lithium.
Anwendungsgebiet: Anwendungsbereich sind Depressionen aller Art wie reaktive, zyklische etc. Area of application: The area of application are all types of depression reactive, cyclical etc.
Zweck: Dieses Antidepressivum soll Depressionen aller Genese besseren. (I,angzeittherapeutikum). Klinisch und ambulant anzuwenden. Purpose: This antidepressant is supposed to improve depression of all origins. (I, angzeittherapeutikum). To be used clinically and on an outpatient basis.
Stand der Technik mit Fundstellen: Seither werden Depressionen vor allem mit Antidrepessiva sowie mit Lithiumsalzen behandelt: Li2S04, Li2CO3 etc' Diese Salze lösen sich sofort im Blut auf und werden durch die Niere ausgeschieden. State of the art with references: Since then, depression has been prevalent treated mainly with antidrepessants and lithium salts: Li2S04, Li2CO3 etc ' These salts immediately dissolve in the blood and are excreted by the kidney.
Kritik des Standes der Technik: Die verwendeten Lithiumsalze und auch die organischen Antidepressiva sind nicht genügend geeignet, den den Depressionen zugrundeliegenden Dopaminmangel zu substituieren. Eine ausreichende Substitution wird aber mit dem erfundenen Komplex aus Lithium und Dimethandrostenolon erzielt. Er durchdringt die Blut-Hirn-Schranke und substituiert in den Gehirngebieten das Dopamin vollständig. Criticism of the prior art: The lithium salts used and Even the organic antidepressants are not sufficiently suitable for depression to substitute the underlying dopamine deficiency. Sufficient substitution but is achieved with the invented complex of lithium and dimethandrostenolone. It penetrates the blood-brain barrier and substitutes it in the brain areas Dopamine completely.
Aufgabe: Der Erfindung liegt die Aufgabe zugrunde, den bei Depicssionen vorhandenen Dopaminmangel optimal zu beseitigen, indem das Lithium so organisch gebunden verabreicht wird, daß der ganze Komplex ohne vorherigc Metabaolisierung die Kerngebiete (nucl. niger, caudatus etc) erreicht und hier den Dopaminmangel beheben kann. Task: The invention is based on the task at Depicssionen to optimally eliminate existing dopamine deficiency by making the lithium so organic The whole complex is administered bound without prior metabaolization reaches the core areas (nucl. niger, caudatus etc) and here the dopamine deficiency can fix.
Lösung: Dieses Problem wird dadurch gelöst, daß eine Verbindung aus Lithium und methyliertem Methandrostenolon (= Dimethandrostenolon) hergestellt wird. Das Methandrostenolon ist schon als Anabolikum in Gebrauch. Solution: This problem is solved by making a connection from Lithium and methylated methandrostenolone (= dimethandrostenolone) is produced. Methandrostenolone is already in use as an anabolic steroid.
Die Methylierung dieser Substanz ist aber neu. Damit soll eine Eliminierung einer Virisilierung dieses Testosteronpräparates erreicht werden. Die Methylierung erfolgt (siehe Zeichnungen), indem Methandrostenolon (= Dianabol) in stöchiometrisch gleicher Menge mit CH1CI erhitzt wird. Dabei entsteht Dimethandrostenolon.The methylation of this substance is new. This is supposed to be an elimination a viralization of this testosterone preparation can be achieved. The methylation takes place (see drawings) by taking Methandrostenolon (= Dianabol) in stoichiometric the same amount is heated with CH1CI. This creates dimethandrostenolone.
I)ic Reaktion der Anlagerung von Lithium erfolgt so: Das LiSO4 wird mit Dimethandrostenolon erhitzt. I) ic reaction of the addition of lithium takes place as follows: The LiSO4 becomes heated with dimethandrostenolone.
(BaCl2 und Petroläther als Zusatz). Dabei entsteht Lithium- Dimethandrostenolon.(BaCl2 and petroleum ether as additives). This creates lithium dimethandrostenolone.
Weitere Ausgestaltung der Erfindung. Further embodiment of the invention.
Spektralanalytischer Nachweis des Li-Dimethandroste- nolon.Spectral analytical detection of the Li-Dimethandroste- nolone.
Erzielbare Vorteile: Die mit der Erfindung erzielten Vorteile bestehen darin, daß anstatt einer Anzahl von mehr oder weniger wirkenden Antidepressiva ein Langzeittherapeutikum effektiver Art vorliegt. Das Dopamin wird effektiv substituiert. Achievable Advantages: The advantages achieved with the invention exist that instead of a number of more or less effective antidepressants Long-term therapeutic agent of an effective type is present. The dopamine is effectively substituted.
Beschreibung eines oder mehrerer Ausführungsbeispiele: (siehe Zeichnungen) - L e e r s e i t e - Description of one or more exemplary embodiments: (see drawings) - L e r s e i t e -
Claims (3)
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1769289A1 (en) | Method and device for extracting a daughter radio isotope from a mother radio isotope | |
| AT389226B (en) | Process for the production of an analgesic and antiinflammatory pharmaceutical preparation | |
| DE2357308A1 (en) | CATHETER | |
| DE2417859A1 (en) | PROCESS FOR MANUFACTURING MIXED HEPARINE SALT | |
| DE3038604A1 (en) | USE OF POLYALKYLENE GLYCOL FOR TREATING SKIN DISEASES | |
| DE3517998C1 (en) | ||
| Gallen | Toward an understanding of follow-up research with alcoholics | |
| DE4404990C1 (en) | Process for producing a sterile prednisolone gel | |
| DE3517998A1 (en) | Antidepressant consisting of a compound from methylated methandrostenolone (= dimethandrostenolone) and elemental lithium | |
| DE2161588C3 (en) | Agents for the treatment of hyperlipoproteinemia | |
| DE3216026A1 (en) | TECHNETIUM (99M) MARKED ISONICOTINIC HYDRAZIDE, METHOD FOR THE PRODUCTION THEREOF AND A PHARMACEUTICAL AGENT CONTAINING THIS COMPOUND | |
| DE649665C (en) | Process for the preparation of durable solutions from morphine hydrochloride for injection purposes | |
| DE202018103853U1 (en) | Composition for application of curcumin | |
| DE3023396C2 (en) | Medicines for intravenous cancer therapy | |
| DE2357864A1 (en) | Anti-diabetic agents prepn. - from biguanidine (salt) and nicotinic acid (salt) | |
| DE308151C (en) | ||
| Kaelin et al. | Multiresistente Tuberkulose | |
| DE833839C (en) | Process for the preparation of water-soluble double compounds of antihistamines | |
| DD139519A1 (en) | METHOD FOR PRODUCING ANALGETIC FORMULATIONS WITH IMPROVED UTILITY CHARACTERISTICS | |
| Buschke | 31 MeV Röntgentherapie | |
| Kienle et al. | Können aus der Studie «Komplemtentärmedizin in der Krankenversicherung» wissenschaftlich tragfähige Schlüsse gezogen werden? | |
| DE19721495A1 (en) | Infusion apparatus for patients | |
| Ruh | Ethik und Risiko | |
| Klein | Brustkrebs individuell behandeln | |
| DE3017032A1 (en) | A CLEAR INJECTION OR INFUSION SOLUTION CONTAINING A SULPHONAMIDE AND A POTENTIAL |